ongoing

RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer.

The primary objective of RADICAL PC1 is to determine the prevalence of cardiovascular risk factors and disease, and the incidence of major adverse cardiovascular events in men with prostate cancer and in particular men treated with Androgen Deprivation Therapy.

RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.

The primary objective of RADICAL PC2 is to determine whether a systematic cardiovascular and lifestyle risk factor modification strategy reduces the risk of major adverse cardiovascular events in men with a new diagnosis of prostate cancer or who are commencing Androgen Deprivation Therapy for the first time.

Study Type

Observational

Study Design

Observational

NO. of Countries

1

NO. of Sites

18

NO. of Participants

6000

Study Period

2015 - 2025

Sponsor

PHRI

Prostate Cancer Canada

Canadian Cancer Society

Hamilton Health Sciences

Back To Top